What changed

Boltz PBC, a startup that develops artificial intelligence models for pharmaceutical researchers, has raised $110 million in funding. Bessemer led the Series A investment, with participation from a large group of new and returning backers, including Greycroft, Andreessen Horowitz, Amplify Partners, F-Prime Capital, Hummingbird, and others.

What this means in practice

Boltz offers an AI model called BoltzMol-1 that accelerates the drug discovery workflow by generating binding affinity data using only a few dozen particularly promising molecules instead of the hundreds of thousands typically required. This reduces the time and cost of analysis.

The model was tested across 10 challenging and therapeutically-relevant targets, with small molecule hits identified for six of them.

Scientists can adapt BoltzMol-1 to project-specific constraints, such as limiting the model to small molecules that can be made from a limited set of compounds.

Boltz also provides a second model, BoltzProt-1, which generates tens of thousands of protein designs based on data from small molecule hits and evaluates them using direct metrics, showing higher success in internal tests compared to competing models.

Limitations and availability

Boltz sells its algorithms via an API billed based on token usage. Customers’ token consumption has grown by a factor of 50 since the models launched in June. The company counts six of the world’s 20 largest pharmaceutical companies as clients.

The new funding will be used to grow the team and procure more computing infrastructure to keep pace with leading AI labs like Anthropic PBC and OpenAI Group.

Boltz has already started training a new generation of molecule design algorithms, which it claims show substantial improvements over current models.

Source facts for Medical AI Startup Boltz Raises $110M to Accelerate Small Molecule Research: Boltz PBC, a startup that develops artificial intelligence models for pharmaceutical researchers, has raised $110 million in funding. Bessemer led the Series A investment. Boltz stated on Wednesday that the fund was joined by a large group of new and returning backers.
Original AINewsTrend explainer based on the cited source. This graphic summarizes source statements; it is not an independent benchmark.

Sources and further reading

  1. siliconangle: Medical AI startup Boltz raises $110M to speed up small molecule research